victrelis (boceprevir) and ritonavir-boosted human immunodeficiency virus (hiv) protease inhibitor drugs

FDA News Victrelis (boceprevir) and Ritonavir-Boosted Human Immunodeficiency Virus (HIV) Protease Inhibitor Drugs - Drug Interactions Richard Klein & Kimberly Struble
February 9, 2012

Food and Drug Administration - February 9, 2012 The U.S. Food and Drug Administration (FDA) is notifying healthcare professionals and patients that drug interactions between the hepatitis C virus (HCV) protease inhibitor Victrelis (boceprevir) and certain ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitors (atazanavir, lopinavir, darunavir) can potentially reduce the effectiveness of these medicines when they are used together.

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Photographs from A Day with HIV Now Online Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 COLORADO: Boulder Groups Honor More Than 150 Local AIDS Victims PENNSYLVANIA: Area Residents Screened for Hepatitis C on Sunday COLORADO: Peer to Peer: Teens Work to Educate Peers on Pregnancy, STDs at CCHS OREGON: Portland Barefoot 3 x 3 Benefit Tournament to Draw Hundreds to Northeast Portland TEXAS: Temple - Wellness and Sexual Health Classes Helping Kids to Abstain CONNECTICUT: Yale Researchers Urge More Street Work When Studying People With Both HIV, Hepatitis C JAMAICA: AIDS Awareness Workshop Organised for High-School Students EUROPE: EU Issues Stringent Sharps Regulations CALIFORNIA: $50,000 Prisoner Prescription: Inmates Get Expensive Hepatitis C Treatment Tentative approval of lamivudine and tenofovir disoproxil fumarate Tablets, 300 mg/300 mg CONNECTICUT: Yale Researchers Urge More Street Work When Studying People With Both HIV, Hepatitis C General Secretariat of the League of Arab States and UNAIDS to work toward an accelerated HIV response in the Arab Region OHIO: Cleveland LGBT Community Center Offers Free Support Groups and HIV, STD Testing: The Frugal Patient CALIFORNIA: Local Church Sends HIV/AIDS Care Packs to Swaziland ITALY: HIV Is No Barrier to Successful Liver Transplant for Cancer Treatment UNITED STATES: Navajo Confront an Increase in New H.I.V. Infections Uganda: HIV Vaccine Trials to Start in July Uganda: Remembering Those Killed By HIV/AIDS (International AIDS Candlelight Memorial)Navajo Confront an Increase in New H.I.V. Infections TB, HIV and malaria vaccine research gets major boost
Copyright © 2012 -FDA News, Publisher. All rights reserved to Food and Drug (FDA) Administration FDA. Information in this article was accurate in February 9, 2012. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.